Zobrazeno 1 - 10
of 122
pro vyhledávání: '"Reynolds Dominic"'
Autor:
Neil, Christopher R., Seiler, Michael W., Reynolds, Dominic J., Smith, Jesse J., Vaillancourt, Frédéric H., Smith, Peter G., Agrawal, Anant A.
Publikováno v:
In Trends in Pharmacological Sciences May 2022 43(5):437-454
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
David M. Bolduc, Nicholas A. Larsen, Stephanos Ioannidis, Federico Colombo, Toung-Vi Nguyen, Frédéric H. Vaillancourt, Alan Rolfe, Lihua Yu, Ping Zhu, Andrew Cook, Milena Virrankoski, Reynolds Dominic, Kiyoyuki Omoto, Shihua Yao
Publikováno v:
ACS Med Chem Lett
[Image: see text] Carbamoyl phosphate synthetase 1 (CPS1) is a potential synthetic lethal target in LKB1-deficient nonsmall cell lung cancer, where its overexpression supports the production of pyrimidine synthesis. In other cancer types, CPS1 overex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e65eb58d3e5de871c2ef8af973dc3067
https://europepmc.org/articles/PMC7294722/
https://europepmc.org/articles/PMC7294722/
Autor:
Sean Eckley, Markus Warmuth, Ping Zhu, Deepti Banka, Zhenhua J. Wu, Nicholas A. Larsen, Sudeep Prajapati, Ricardo Ribas, Ming-Hong Hao, Pavan Kumar, Pete Smith, Michael J. Wick, Kiran Aithal, Crystal Mackenzie, John D. Norris, Sasirekha Sivakumar, V. Subramanian, Tuong-Vi Nguyen, Lihua Yu, Sean Irwin, Andrew Hart, Craig Furman, Alyssa Moriarty, Amy Kim, Benjamin Caleb, O'shea Morgan Welzel, Craig Karr, Sunil Pancholi, Frédéric H. Vaillancourt, Silvia Buonamici, Manav Korpal, Namita Kumar, Weidong G. Lai, Diana Melchers, Peter Fekkes, René Houtman, Lesley-Ann Martin, Xiaoling Puyang, Victoria Rimkunas, Michael Thomas, Amy Siu, Reynolds Dominic, Sujatha Rajagopalan, Suzanne E. Wardell, John Wang, Jaya Julie Joshi, Zheng Guo Zhu, David M. Bolduc, Nathalie Rioux, Subhasree Das, Sergei Agoulnik, Shihua Yao, Galina Kuznetsov
Publikováno v:
Cancer Discovery. 8:1176-1193
Mutations in estrogen receptor alpha (ERα) that confer resistance to existing classes of endocrine therapies are detected in up to 30% of patients who have relapsed during endocrine treatments. Because a significant proportion of therapy-resistant b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0120259fcf7ad9215e86543a6ac089d0
https://doi.org/10.1158/2159-8290.cd-17-1229
https://doi.org/10.1158/2159-8290.cd-17-1229
Autor:
Sean Irwin, Guo-Zhu Zheng, Sherri Smith, Craig Furman, Deepti Banka, Nathalie Rioux, Victoria Rimkunas, J Norris, Prashant Kumar, Nicholas A. Larsen, Y Yu, Anand Selvaraj, Sergei Agoulnik, Craig Karr, Andrew Hart, T Bowser, Lorna Helen Mitchell, Crystal MacKenzie, Huilan Yao, Pete Smith, Tarek Sahmoud, Peter Fekkes, Jiayi Wu, T-V Nguyen, Zhaojie Zhang, Frédéric H. Vaillancourt, Betty Chan, Mike Thomas, Benjamin Caleb, O'shea Morgan Welzel, Manav Korpal, Markus Warmuth, Ping Zhu, S Wardell, Amy K. Kim, Galina Kuznetsov, Sean Eckley, Allison Davis, Sudeep Prajapati, Jun Wang, Ming-Hong Hao, V. Subramanian, Naresh Kumar, Xiaoling Puyang, Lihua Yu, Jaya Julie Joshi, Reynolds Dominic, G W Lai
Publikováno v:
Cancer Research. 78:P1-10
Mutations in estrogen receptor alpha (ERα) are detected in up to 30% of breast cancer patients who have relapsed during endocrine therapy. ERα mutations functionally confer resistance to existing classes of endocrine therapies, likely through gaini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07d855e8c12d90a391ebb18e38827bdf
https://doi.org/10.1158/1538-7445.sabcs17-p1-10-08
https://doi.org/10.1158/1538-7445.sabcs17-p1-10-08
Autor:
Suzanna L. Bailey, Pete Smith, Victoria Rimkunas, Raelene Hurley, Kun Yu, Lihua Yu, Craig Karr, Ping Zhu, Markus Warmuth, Reynolds Dominic, Takashi Satoh, Anand Selvaraj, Silvia Buonamici, Jennifer Tsai, Erik Corcoran, Jaya Julie Joshi, Crystal MacKenzie, Chia-Ling Huang, Nicholas A. Larsen, Weidong G. Lai, Nathalie Rioux, Amy Kim, Eunice Park, Pavan Kumar, Peter Fekkes, V. Subramanian, Sudeep Prajapati, John Q. Wang, Kana Ichikawa, Heather Coffey, Jeremy Wu, Ming-Hong Hao
Publikováno v:
Cancer Research. 77:6999-7013
Activation of the fibroblast growth factor receptor FGFR4 by FGF19 drives hepatocellular carcinoma (HCC), a disease with few, if any, effective treatment options. While a number of pan-FGFR inhibitors are being clinically evaluated, their application
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeb539ae317631dc715dd09389dfc34a
https://doi.org/10.1158/0008-5472.can-17-1865
https://doi.org/10.1158/0008-5472.can-17-1865
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Markus Warmuth, Manav Korpal, Deepti Banka, Peter Fekkes, Pavan Kumar, Andrew Hart, Lihua Yu, Ping Zhu, Lorna Helen Mitchell, Joyce Yang, W. George Lai, Amy Kim, Craig Karr, Pete Smith, Tarek Sahmoud, Xiaoling Puyang, Sherri Smith, Mike Thomas, Benjamin Caleb, O'shea Morgan Welzel, Victoria Rimkunas, Huilan Yao, Sean Eckley, Allison Davis, Silvia Buonamici, Crystal MacKenzie, V. Subramanian, Jeremy Wu, Zheng Guo Zhu, Christopher Rowbottom, Reynolds Dominic, Nicholas A. Larsen, Nathalie Rioux, Sean Irwin, Craig Furman
Publikováno v:
Cancer Research. 77:DDT01-04
Mutations in the estrogen receptor (ER) are detected in up to 30% of patients that initially respond but subsequently relaps to anti-endocrine therapies. ERα mutations, likely through constitutively activating ERα, can functionally confer resistanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71b5b0fa7e9d8e6795b2dcf66171548d
https://doi.org/10.1158/1538-7445.am2017-ddt01-04
https://doi.org/10.1158/1538-7445.am2017-ddt01-04
Autor:
Sudeep Prajapati, Ming-Hong Hao, Ping Zhu, Victoria Rimkunas, Guo Z. Zheng, Craig Furman, Manav Korpal, Reynolds Dominic
Publikováno v:
Cancer research. 79(8)
The development of tamoxifen and subsequent estrogen receptor alpha (ERα) antagonists represents a tremendous therapeutic breakthrough in the treatment of breast cancer. Despite the ability of ERα antagonists to increase survival rates, resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6c380156172f5e91aab9ed8b8979765
https://pubmed.ncbi.nlm.nih.gov/30952631
https://pubmed.ncbi.nlm.nih.gov/30952631